+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Novo Nordisk

  • ID: 5357322
  • Company Profile
  • January 2021
  • 64 pages
  • Datamonitor Healthcare
  • Novo Nordisk A/S
The publisher explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Novo Nordisk continues to dominate the diabetes segment, but pricing pressure in the US will dampen overall sales growth during the forecast period.
  • Key Themes - [1] Novo Nordisk will maintain its dominance in diabetes with the launch of Rybelsus [2] Growth in Rest of World regions, especially China, is key to Novo Nordisk’s long-term revenue outlook [3] US volume growth and market share will remain strong, but pricing pressures, discounts, and rebates will limit revenue growth [4] Insulin biosimilars are a key risk to Novo Nordisk’s insulin franchises, but limited impact seen to date.
Model updates (4 November 2020)
  • Tresiba forecast adjusted lower in the US due to pricing pressures on insulins; long-term forecast adjusted higher due to later loss of exclusivity
  • Xultophy forecast adjusted lower in the US due to pricing pressures on insulins
  • Levemir forecast adjusted lower in the US due to pricing pressures on insulins
  • FIAsp forecast adjusted lower in the US due to pricing pressures on insulins
  • Victoza forecast adjusted higher in Rest of World due to less Ozempic cannibalization to date
  • Ozempic forecast adjusted higher in the US and Europe for diabetes; forecast adjusted higher globally due to obesity launches in 2022+
  • Saxenda forecast adjusted lower in the US due to lower sales
  • Somapacitan name changed to Sogroya due to approval; forecast adjusted lower in ex-US markets to align with expected approval timeline.
Model updates (7 August 2020)
  • Ozempic forecast adjusted lower in the US
  • Rybelsus forecast adjusted higher in the US
  • Levemir forecast adjusted lower in the US
  • Tresiba forecast adjusted lower in the US.
Model updates (2 June 2020)
  • Esperoct forecast adjusted lower.
Model updates (6 March 2020)
  • Tresiba forecast adjusted lower in the US due to continued pricing pressure
  • Xultophy forecast adjusted lower in the US due to continued pricing pressure
  • Levemir forecast adjusted lower in the US due to continued pricing pressure
  • NovoMix forecast adjusted lower in the US due to continued pricing pressure
  • NovoRapid forecast adjusted lower in the US due to continued pricing pressure
  • Victoza forecast adjusted lower in the US due to patient shifts to Ozempic
  • Ozempic forecast adjusted higher globally due to continued market share gains and GLP-1 class growth
  • Rybelsus forecast adjusted lower due to slower launch trend
  • Saxenda forecast adjusted lower due to future generic competition.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Notable Quotes & Important Topics
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll